Ocugen is a biotechnology company developing gene therapies and other innovative products for severe eye diseases and significant medical needs. The company's core platform is a modifier gene therapy technology based on nuclear hormone receptors that uses a gene-agnostic approach to target multiple genetic mutations with a single treatment, with lead programs addressing retinitis pigmentosa, Stargardt disease, and geographic atrophy, as well as emerging programs in diabetic eye disease, age-related macular degeneration, and cartilage repair. Ocugen generates revenue through co-development and licensing agreements with global pharmaceutical partners, regulatory approvals and commercial sales of approved therapies, and milestone and royalty payments from strategic partnerships, while funding clinical development through partnerships like the federally-funded Project NextGen initiative for its vaccine candidates.